美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!

2016-02-09 MedSci MedSci原创

美国癌症协会(ACS)每5年要发布一期关于饮食、营养和体育运动与癌症预防之间关系的报告,作为对大众的科学知识普及、各卫生健康机构和社区团体之间的交流和有关政策方针制定的指南。 研究结果显示,中国每年新增癌症患者占到全球新增患者的20%以上,该指南推荐可以较为客观的阐述和回答患者和家属疑惑的问题,希望大家本着科学的态度去看待问题,不要轻信谣言,害人害己。 1、乳腺癌 美国妇女最多见的肿瘤,为妇

美国癌症协会(ACS)每5年要发布一期关于饮食、营养和体育运动与癌症预防之间关系的报告,作为对大众的科学知识普及、各卫生健康机构和社区团体之间的交流和有关政策方针制定的指南。总共有三十一条,全部在这里:美国癌症协会(ACS)权威发布:三十一条防癌指南,下面汇集常见的肿瘤与饮食之间的关系,给大家参考。

研究结果显示,中国每年新增癌症患者占到全球新增患者的20%以上,该指南推荐可以较为客观的阐述和回答患者和家属疑惑的问题,希望大家本着科学的态度去看待问题,不要轻信谣言,害人害己。

1、乳腺癌

美国妇女最多见的肿瘤,为妇女第二大死亡原因的癌症,仅次于肺癌。绝经后妇女体重超重,则患乳腺癌的风险显著增加。这与过多脂肪导致血内雌激素水平过高有关。过多饮酒并叶酸摄入不足也会增加乳腺癌发生的风险。体育锻炼可降低这一风险。

2、结、直肠癌

在美国因癌症死亡总人数中居于第2位。肥胖与其有直接关系,男性尤其显著。大量摄入蔬菜水果和含粗纤维谷物,减少红肉及加工肉类食品的摄入,适当摄入维生素D和钙,同时加强日常的体育锻炼可以降低其发生的风险。另外,定期筛检、及时发现和切除肠道腺瘤(癌前病变)也至关重要。

美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!

3、子宫内膜癌

美国妇女癌症发病率中居第4位。子宫内膜癌与雌激素水平有关。通过大量运动,增加蔬菜、水果、粗纤维食品及豆类的摄入,保持健康体重均可降低其发生的可能性。

4、肺癌

美国因癌症死亡的第一大因素。超过85%的患者发病与烟草有关。戒烟和大量摄入蔬菜水果有助于降低其发生。但要注意:过量食用含胡萝卜素和维生素A的保健食品反而会使吸烟者的肺癌发生危险系数升高。

美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!

5、肾癌

占男性癌症发病及死亡的3%、女性的2%。直接相关因素有肥胖和吸烟。因此,戒烟及保持健康体重尤为重要。

6、胰腺癌

美国癌症死亡原因的第4位。吸烟、2型糖尿病、过多食用红肉及体育运动不足与其极为相关。其中,比较有名的胰腺癌患者,就是“苹果教父”乔布斯。

美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!

7、上呼吸道和消化道癌症

酗酒、吸烟显著增加口腔癌、咽喉癌和食管癌的可能。饮食过热导致食道灼伤,可引发食管的慢性炎症最终恶化为食管癌。改变不良饮食习惯,戒烟酒,减轻体重和多食新鲜蔬菜及水果有利于降低其发生的风险。

8、胃癌

为全球第4位常见癌症和死亡率第二的癌症。胃癌的发生主要由于过多摄入腌制食品和胃幽门螺旋菌感染而导致慢性胃炎和胃溃疡所致。

美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!

9、 前列腺癌

美国男性中最常见的癌症。多食用西红柿、菜花、豆类及鱼肉有助于降低其发生风险。维生素E和硒及相应辅助保健食品的保护作用目前尚无确定结论。过多钙摄入则与高度恶性前列腺癌有关,故不提倡摄入过量钙或补充过量钙片。另外,统计发现超重和肥胖的前列腺癌患者治疗效果不佳。

10、膀胱癌

与吸烟和某些化工物质有关。资料显示大量食用蔬菜水果、大量饮水有助于降低其发生危险。 同时,卵巢癌以及其他恶性肿瘤如脑瘤、淋巴瘤和白血病等,目前尚未发现与营养、饮食、体重有显著相关性。

美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!

缺乏这4种营养,最容易招癌

在癌症日益多发的今日,适当的了解一些有关于缺乏营养而诱发癌症的知识是很重要的。

缺乏β-胡萝卜素:可诱发肺癌

目前,肺癌仍是我国发病率最高的癌症。除了吸烟、吸入过多油烟等因素会导致肺癌以外,人体若缺乏β-胡萝卜素也可能诱发肺癌。因此,长期吸烟者、肺结核患者和矽肺患者等易患肺癌的人应多吃富含β-胡萝卜素的食物,如甘薯、胡萝卜、菠菜、芒果、木瓜和豆腐等。

缺乏蛋白质:可诱发胃癌

若饮食中摄入的蛋白质不足,尤其是摄入的优质蛋白质不足,就可能诱发胃癌。在过去,胃癌一度被称为“穷病”。此外,人们若大量食用腌制的咸鱼、咸菜等含有亚硝胺等致癌物质的食物,也会增加患胃癌的几率。

因此,萎缩性胃炎患者、胃溃疡患者、免疫功能低下者及有胃癌家族史者等易患胃癌的人应常吃富含优质蛋白质的食物,如深海鱼虾、牡蛎、大豆、瘦肉和鸡蛋等。

美国癌症协会发布“防癌指南”:科学看问题,不轻信谣言!【不爱吃生冷食物的人,可以选择熟食】

缺乏膳食纤维:可诱发结肠癌

在现代人的饮食结构中,高脂肪、高蛋白食物所占的比例越来越大,而膳食纤维的摄入量却日渐减少。

在缺乏膳食纤维的情况下,这些致癌物质会长时间地停留在结肠粘膜上,从而可诱发结肠癌。玉米是膳食纤维含量比较高的食物,不妨可以多吃。

缺乏维生素D:可诱发乳腺癌

大量临床调查数据都表明,乳腺癌患者体内的维生素D含量往往较低。加拿大的研究人员还发现,体内缺乏维生素D的乳腺癌患者和体内不缺乏此物质的乳腺癌患者相比,其病死率相对较高。

因此,有乳腺癌家族史者,未生育的女性、中老年女性、月经初潮较早或绝经较晚的女性等易患乳腺癌的人应多吃鱼肉、牛肉、猪肝和鸡蛋黄等富含维生素D的食物,并应经常晒太阳,以促使机体合成更多的维生素D。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-03-21 忠诚向上

    继续了解

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-03-21 忠诚向上

    继续了解

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-03-21 忠诚向上

    继续了解

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-03-21 忠诚向上

    继续了解

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-03-21 忠诚向上

    继续了解

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-03-21 忠诚向上

    继续了解

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1661296, encodeId=0f22166129674, content=<a href='/topic/show?id=89bd9212273' target=_blank style='color:#2F92EE;'>#谣言#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92122, encryptionId=89bd9212273, topicName=谣言)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f625261446, createdName=ms2999106592497887, createdTime=Tue Dec 20 16:17:00 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045307, encodeId=3efe204530e1c, content=<a href='/topic/show?id=1b21e1326fa' target=_blank style='color:#2F92EE;'>#癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71326, encryptionId=1b21e1326fa, topicName=癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 14 15:17:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032133, encodeId=55ad203213391, content=<a href='/topic/show?id=35b3e9841cd' target=_blank style='color:#2F92EE;'>#美国癌症协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79841, encryptionId=35b3e9841cd, topicName=美国癌症协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=shuangle, createdTime=Wed Sep 21 07:17:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72171, encodeId=ceade21712a, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72172, encodeId=d02ce21722d, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72173, encodeId=ae05e21739b, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72174, encodeId=1f1ee217440, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72175, encodeId=f689e21755e, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72176, encodeId=9c26e2176a2, content=继续了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 21 18:18:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64016, encodeId=9f5764016a5, content=对症下药。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2cee1686934, createdName=1de4ac4em35(暂无匿称), createdTime=Thu Feb 11 21:38:00 CST 2016, time=2016-02-11, status=1, ipAttribution=)]
    2016-02-11 1de4ac4em35(暂无匿称)

    对症下药。。。

    0

相关资讯

世界癌症组织提倡的防癌心得 不想得癌必看!

阅读提要:防癌究竟怎么吃才最好?美国癌症研究所与世界癌症研究基金会撰写的《食物、营养与癌症预防》中指出,如果能做到合理膳食、经常运动和保证正常体重,可以降低30%~40%癌症的发生风险。 专家: 康景轩,美国哈佛大学医学院脂类医学与技术研究中心主任、博士,世界营养基因组学学会秘书长。 郝希山,中国工程院院士 爱德华多·卡加普,国际抗癌联盟前主席 防癌究竟怎么吃才最好?美国癌症研究所与

癌字三个口,猴年九道防癌菜,理想的新春礼物!

猴年伊始,小编祝大家新春快乐,但最好的新年祝福莫过于每个人都有一个健康的身体。 重庆市肿瘤医院院长、肿瘤专家周琦介绍,癌字里面三个口,60%以上的癌症都与吃有关。今天教大家9道防癌菜,让您猴年远离癌症! 1、蒜泥白肉——防胃癌 经常食用大蒜,可使患肠癌的风险降低30%,而且常吃生大蒜的人,胃癌发病率非常低。 这是因为大蒜能显著降低胃中亚硝酸盐含量,从而减少胃癌发生的诱因。蒜泥白肉这道菜

AJCN:水果蔬菜能够显著减少肾癌发生风险

    有关水果蔬菜能否预防肾细胞癌争议尤来以久,虽在有一些研究认为二者无关,往往是因为样本人群选择存在偏倚所致。目前更多的研究(大样本,长期随访)结果认为确实可以降低肾细胞癌。最新一项在美国人群中的登记研究,针对NIH-AARP饮食和健康研究,跟踪了多达491841人,通过调查其人口学资料,饮食,生活方式,以及病史,其中发生肾透明细胞癌患者1816例,并平均随访超过

国际癌症研究机构发布12条防癌建议

世界卫生组织下属的国际癌症研究机构14日发布最新版欧洲地区防癌准则,向欧洲公众提供12条预防癌症建议。 第一部分建议与烟、酒及饮食有关,包括不要吸烟、不使用任何烟草制品;在家中禁止吸烟,支持在工作场所禁烟;食用足量谷物、豆类、水果和蔬菜,少吃热量较高的食物,不喝含糖饮料,避免食用香肠、火腿等肉制品;最好不饮酒,若饮酒须有节制。 第二部分与锻炼及环境防护有关,包括每天应进行体育锻炼,避免久坐;采

中国癌症基金会:防癌记住12条黄金法则

近日,中国癌症基金会提出了“远离癌症十二条”黄金法则,你看看能做到几条。1.远离癌症,切勿吸烟或咀嚼任何烟草类产品。戒烟永不怕迟,你的健康会马上得到改善。戒烟20分钟:升高的血压降到正常;肢体末梢的体温上升到正常。戒烟20分钟:升高的血压降到正常;肢体末梢的体温上升到正常。戒烟8小时:血液中的一氧化碳水平降到正常。总之,戒烟时间越长对人的健康越有利。2.预防感染。一些癌症是由病毒引发的,如接种乙肝

云芝可抗癌

        近日有研究人员表示,癌症治疗的奥秘可能蕴含在一种蘑菇之中。   癌症患者Lisa Clinton说:“当我被诊断出患有癌症的时候,我整个人几乎都僵住了,不敢相信这是真的。”   Lisa无法接受这个事实,她一开始拒绝化疗,好在医务人员最终说服了她,她逐渐振作起来,在治疗期间常常通过跑步来帮助身体恢复。   研究员Leanna&nbs